Research progress on antitumor activity of XRP44X and analogues as microtubule targeting agents.
SAR
XRP44X
antitumor activity
colchicine binding site inhibitors
structural modification
Journal
Frontiers in chemistry
ISSN: 2296-2646
Titre abrégé: Front Chem
Pays: Switzerland
ID NLM: 101627988
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
11
2022
accepted:
20
02
2023
entrez:
20
3
2023
pubmed:
21
3
2023
medline:
21
3
2023
Statut:
epublish
Résumé
Cancer threatens human health and life. Therefore, it is particularly important to develop safe and effective antitumor drugs. Microtubules, the main component of cytoskeleton, play an important role in maintaining cell morphology, mitosis, and signal transduction, which are one of important targets of antitumor drug research and development. Colchicine binding site inhibitors have dual effects of inhibiting proliferation and destroying blood vessels. In recent years, a series of inhibitors targeting this target have been studied and some progress has been made. XRP44X has a novel structure and overcomes some disadvantages of traditional inhibitors. It is also a multifunctional molecule that regulates not only the function of tubulin but also a variety of biological pathways. Therefore, the structure, synthesis, structure-activity relationship, and biological activity of XRP44X analogues reported in recent years were summarized in this paper, to provide a useful reference for the rational design of efficient colchicine binding site inhibitors.
Identifiants
pubmed: 36936533
doi: 10.3389/fchem.2023.1096666
pii: 1096666
pmc: PMC10014799
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1096666Informations de copyright
Copyright © 2023 Wang, Shi, Yang, Chang, Liu, Zeng, Meng, Zhang and Xing.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Bioorg Chem. 2021 Jul;112:104965
pubmed: 34020238
Eur J Med Chem. 2022 Jul 5;237:114372
pubmed: 35447432
Bioorg Chem. 2021 Jan;106:104199
pubmed: 33317837
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Med Chem. 2009 Apr 9;52(7):1864-72
pubmed: 19296651
Clin Cancer Res. 2014 Sep 1;20(17):4442-8
pubmed: 24958807
Gene Expr. 2015;16(4):197-203
pubmed: 26637400
Eur J Med Chem. 2021 Dec 5;225:113749
pubmed: 34411892
Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19151-6
pubmed: 20974907
J Med Chem. 2014 Aug 14;57(15):6795-808
pubmed: 25025853
Bioorg Chem. 2020 Nov;104:103909
pubmed: 33142419
Free Radic Biol Med. 2010 Mar 15;48(6):749-62
pubmed: 20045723
J Enzyme Inhib Med Chem. 2021 Dec;36(1):549-560
pubmed: 33522315
Sci Rep. 2017 Dec 7;7(1):17120
pubmed: 29215079
Eur J Cell Biol. 2020 May;99(4):151075
pubmed: 32414588
Oncotarget. 2016 Oct 4;7(40):65137-65146
pubmed: 27556500
J Med Chem. 2016 Apr 14;59(7):3439-51
pubmed: 26938120
J Med Chem. 2020 Oct 8;63(19):10618-10651
pubmed: 32432867
Curr Med Chem. 2020;27(40):6787-6814
pubmed: 31580244
J Med Chem. 2013 Nov 27;56(22):9008-18
pubmed: 24160376
Nat Biotechnol. 2010 Jun;28(6):600-5
pubmed: 20512121
Sci Transl Med. 2016 Nov 16;8(365):365ra159
pubmed: 27856798
Eur J Med Chem. 2018 Jan 1;143:806-828
pubmed: 29223097
J Med Chem. 2012 Jan 12;55(1):475-88
pubmed: 22136312
Cancer Res. 2008 Mar 1;68(5):1275-83
pubmed: 18316589
Dev Reprod. 2020 Mar;24(1):53-62
pubmed: 32411918
Anticancer Drugs. 2012 Jan;23(1):98-107
pubmed: 21968419
J Med Chem. 2012 Mar 8;55(5):2144-53
pubmed: 22332894
Oncol Rep. 2017 Feb;37(2):813-822
pubmed: 27959451
J Enzyme Inhib Med Chem. 2021 Dec;36(1):640-658
pubmed: 33588683
Arch Pharm (Weinheim). 2014 Jun;347(6):449-55
pubmed: 24623369
Bioorg Chem. 2021 Oct;115:105239
pubmed: 34399321
Bioorg Chem. 2022 May;122:105735
pubmed: 35298962